| Price | $2.11 |
| Year Range | $2.13 – $5.95 |
| Market Cap | $224M |
| Industry | Biotechnology |
What Is Larimar Therapeutics’s AI Stock Analysis?
Larimar Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Larimar Therapeutics’s momentum in near-real time.
Larimar Therapeutics (LRMR) has an AltIndex AI Score of 49/100, currently a Hold signal. The AI Score distills Larimar Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Larimar Therapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Larimar Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving LRMR’s AI Score?
Fundamentals
Revenue for the last quarter was $0. This is equal to the revenue of the quarter before it, showing stability. Also, this is equal to the revenue of the same quarter last year, indicating consistency. Net income for the last quarter was $-33M. This represents a decrease of 10.70% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 25.21%, which may be a cause for concern. Ebitda for the last quarter was $-33M. This represents a decrease of 10.73% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 25.39%, which may be a cause for concern.
See Larimar Therapeutics’s earnings and insider transactions.
Technicals
Today's stock price is $2.13. This represents a decrease of 43.65% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 49.76%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $2.59, which is lower than the previous SMA10 of $2.68. This suggests a potential downward trend in price movement. The RSI is 53.2, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
Larimar Therapeutics has an estimated 3 open positions and this number has been stable over the last couple of months indicating a company in a stable position. The business outlook among employees at Larimar Therapeutics is low (an estimate of only 0% of employees have a positive outlook), a concerning sign. Larimar Therapeutics has an estimate of 7,000 visitors to their webpage. The number of visitors is up by 17% in the last couple of months, a bullish trend as this can indicate can increase in customers.
Explore Larimar Therapeutics’s job postings, web traffic and app downloads.
Frequently Asked Questions: Larimar Therapeutics AI Stock Analysis
Larimar Therapeutics's AltIndex AI Score is 49/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Larimar Therapeutics a Hold (49/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Larimar Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the LRMR AI Score or sign up to read the full thesis.
